85 related articles for article (PubMed ID: 22483389)
21. Human beta-tryptase is a ring-like tetramer with active sites facing a central pore.
Pereira PJ; Bergner A; Macedo-Ribeiro S; Huber R; Matschiner G; Fritz H; Sommerhoff CP; Bode W
Nature; 1998 Mar; 392(6673):306-11. PubMed ID: 9521329
[TBL] [Abstract][Full Text] [Related]
22. Potent, nonpeptide inhibitors of human mast cell tryptase. Synthesis and biological evaluation of novel spirocyclic piperidine amide derivatives.
Costanzo MJ; Yabut SC; Zhang HC; White KB; de Garavilla L; Wang Y; Minor LK; Tounge BA; Barnakov AN; Lewandowski F; Milligan C; Spurlino JC; Abraham WM; Boswell-Smith V; Page CP; Maryanoff BE
Bioorg Med Chem Lett; 2008 Mar; 18(6):2114-21. PubMed ID: 18272363
[TBL] [Abstract][Full Text] [Related]
23. Dibasic inhibitors of human mast cell tryptase. Part 1: synthesis and optimization of a novel class of inhibitors.
Rice KD; Gangloff AR; Kuo EY; Dener JM; Wang VR; Lum R; Newcomb WS; Havel C; Putnam D; Cregar L; Wong M; Warne RL
Bioorg Med Chem Lett; 2000 Oct; 10(20):2357-60. PubMed ID: 11055355
[TBL] [Abstract][Full Text] [Related]
24. Human tryptase fibrinogenolysis is optimal at acidic pH and generates anticoagulant fragments in the presence of the anti-tryptase monoclonal antibody B12.
Ren S; Lawson AE; Carr M; Baumgarten CM; Schwartz LB
J Immunol; 1997 Oct; 159(7):3540-8. PubMed ID: 9317153
[TBL] [Abstract][Full Text] [Related]
25. Definition of the extended substrate specificity determinants for beta-tryptases I and II.
Harris JL; Niles A; Burdick K; Maffitt M; Backes BJ; Ellman JA; Kuntz I; Haak-Frendscho M; Craik CS
J Biol Chem; 2001 Sep; 276(37):34941-7. PubMed ID: 11438529
[TBL] [Abstract][Full Text] [Related]
26. The B12 anti-tryptase monoclonal antibody disrupts the tetrameric structure of heparin-stabilized beta-tryptase to form monomers that are inactive at neutral pH and active at acidic pH.
Fukuoka Y; Schwartz LB
J Immunol; 2006 Mar; 176(5):3165-72. PubMed ID: 16493076
[TBL] [Abstract][Full Text] [Related]
27. Pyrrole carboxamidine tryptase inhibitors from Leptonychia pubescens.
Yang LK; Ng SP; Flotow H; Yoganathan K; Daramola BO; Soejarto DD; Buss AD; Butler MS
Planta Med; 2005 Nov; 71(11):1071-2. PubMed ID: 16320213
[TBL] [Abstract][Full Text] [Related]
28. Human kallikrein 6 inhibitors with a para-amidobenzylanmine P1 group identified through virtual screening.
Liang G; Chen X; Aldous S; Pu SF; Mehdi S; Powers E; Xia T; Wang R
Bioorg Med Chem Lett; 2012 Apr; 22(7):2450-5. PubMed ID: 22386244
[TBL] [Abstract][Full Text] [Related]
29. Upgrading a natural product: inhibition of human beta-tryptase by cyclotheonamide analogues.
Schaschke N; Sommerhoff CP
ChemMedChem; 2010 Mar; 5(3):367-70. PubMed ID: 20077463
[No Abstract] [Full Text] [Related]
30. Synthesis of potent and highly selective nonguanidine azetidinone inhibitors of human tryptase.
Bisacchi GS; Slusarchyk WA; Bolton SA; Hartl KS; Jacobs G; Mathur A; Meng W; Ogletree ML; Pi Z; Sutton JC; Treuner U; Zahler R; Zhao G; Seiler SM
Bioorg Med Chem Lett; 2004 May; 14(9):2227-31. PubMed ID: 15081014
[TBL] [Abstract][Full Text] [Related]
31. 1,2,5-Thiadiazolidin-3-one 1,1-dioxide-based heterocyclic sulfides are potent inhibitors of human tryptase.
Wong T; Groutas CS; Mohan S; Lai Z; Alliston KR; Vu N; Schechter NM; Groutas WC
Arch Biochem Biophys; 2005 Apr; 436(1):1-7. PubMed ID: 15752703
[TBL] [Abstract][Full Text] [Related]
32. Factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of neutral P1 substituents.
Nazaré M; Essrich M; Will DW; Matter H; Ritter K; Urmann M; Bauer A; Schreuder H; Dudda A; Czech J; Lorenz M; Laux V; Wehner V
Bioorg Med Chem Lett; 2004 Aug; 14(16):4191-5. PubMed ID: 15261268
[TBL] [Abstract][Full Text] [Related]
33. Tryptase inhibitors in the treatment of pulmonary diseases.
Gangloff AR
Curr Opin Investig Drugs; 2000 Sep; 1(1):79-85. PubMed ID: 11249600
[No Abstract] [Full Text] [Related]
34. Potent bivalent inhibition of human tryptase-beta by a synthetic inhibitor.
Selwood T; Elrod KC; Schechter NM
Biol Chem; 2003 Dec; 384(12):1605-11. PubMed ID: 14719803
[TBL] [Abstract][Full Text] [Related]
35. Tryptase inhibitors: a patent review.
Ni WW; Cao MD; Huang W; Meng L; Wei JF
Expert Opin Ther Pat; 2017 Aug; 27(8):919-928. PubMed ID: 28425830
[TBL] [Abstract][Full Text] [Related]
36. The role of ecotin dimerization in protease inhibition.
Eggers CT; Wang SX; Fletterick RJ; Craik CS
J Mol Biol; 2001 May; 308(5):975-91. PubMed ID: 11352586
[TBL] [Abstract][Full Text] [Related]
37. Inhibitors of serine proteases as potential therapeutic agents: the road from thrombin to tryptase to cathepsin G.
Maryanoff BE
J Med Chem; 2004 Feb; 47(4):769-87. PubMed ID: 14761180
[No Abstract] [Full Text] [Related]
38. Novel factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of P4 substituents in combination with a neutral P1 ligand.
Nazaré M; Essrich M; Will DW; Matter H; Ritter K; Urmann M; Bauer A; Schreuder H; Czech J; Lorenz M; Laux V; Wehner V
Bioorg Med Chem Lett; 2004 Aug; 14(16):4197-201. PubMed ID: 15261269
[TBL] [Abstract][Full Text] [Related]
39. Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa.
Mederski WW; Dorsch D; Anzali S; Gleitz J; Cezanne B; Tsaklakidis C
Bioorg Med Chem Lett; 2004 Jul; 14(14):3763-9. PubMed ID: 15203158
[TBL] [Abstract][Full Text] [Related]
40. Thermodynamic criterion for the conformation of P1 residues of substrates and of inhibitors in complexes with serine proteinases.
Qasim MA; Lu SM; Ding J; Bateman KS; James MN; Anderson S; Song J; Markley JL; Ganz PJ; Saunders CW; Laskowski M
Biochemistry; 1999 Jun; 38(22):7142-50. PubMed ID: 10353824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
